Pieris Pharmaceuticals, Inc.
Hedge Funds Holdings
Last updated:
Pieris Pharmaceuticals, Inc.‘s stocks are currently a part of 56 hedge funds’ portfolios, which represents 46.16% of the total amount of its stocks outstanding. This makes up a total of 34.21M shares of Pieris Pharmaceuticals, Inc.. Compared to the previous quarter, the number fell by -8.38% or -3.13M shares fewer. As for the holding position changes, 19.64% (11) of current hedge fund investors increased the number of shares held, 32.14% (18) of current holders sold a part of the shares held, and 16.07% (9) closed the holdings completely. 6 hedge funds are new holders of Pieris Pharmaceuticals, Inc. stock in Q3 2022, it is 10.71% of total holders.
Hedge funds holding Pieris Pharmaceuticals (Q4 2017 – Q3 2022)
| Q4 2017 | 90 |
|---|---|
| Q1 2018 | 112 |
| Q2 2018 | 114 |
| Q3 2018 | 104 |
| Q4 2018 | 97 |
| Q1 2019 | 91 |
| Q2 2019 | 92 |
| Q3 2019 | 97 |
| Q4 2019 | 98 |
| Q1 2020 | 94 |
| Q2 2020 | 93 |
| Q3 2020 | 88 |
| Q4 2020 | 82 |
| Q1 2021 | 80 |
| Q2 2021 | 74 |
| Q3 2021 | 76 |
| Q4 2021 | 81 |
| Q1 2022 | 71 |
| Q2 2022 | 65 |
| Q3 2022 | 56 |
Hedge funds changes in Pieris Pharmaceuticals positions (Q4 2017 – Q3 2022)
| Q4 2017 | 30 | 27 | 16 | 6 | 11 |
|---|---|---|---|---|---|
| Q1 2018 | 33 | 54 | 11 | 9 | 5 |
| Q2 2018 | 20 | 44 | 30 | 18 | 2 |
| Q3 2018 | 12 | 39 | 31 | 22 | 0 |
| Q4 2018 | 16 | 35 | 28 | 21 | -3 |
| Q1 2019 | 6 | 23 | 30 | 13 | 19 |
| Q2 2019 | 15 | 24 | 34 | 12 | 7 |
| Q3 2019 | 19 | 28 | 30 | 14 | 6 |
| Q4 2019 | 23 | 27 | 31 | 22 | -5 |
| Q1 2020 | 16 | 30 | 30 | 19 | -1 |
| Q2 2020 | 11 | 33 | 25 | 11 | 13 |
| Q3 2020 | 10 | 22 | 34 | 15 | 7 |
| Q4 2020 | 10 | 27 | 20 | 15 | 10 |
| Q1 2021 | 6 | 22 | 28 | 8 | 16 |
| Q2 2021 | 24 | 11 | 29 | 30 | -20 |
| Q3 2021 | 24 | 17 | 16 | 22 | -3 |
| Q4 2021 | 21 | 20 | 22 | 15 | 3 |
| Q1 2022 | 9 | 24 | 19 | 19 | 0 |
| Q2 2022 | 10 | 15 | 25 | 16 | -1 |
| Q3 2022 | 6 | 11 | 18 | 9 | 12 |
Hedge funds changes in Pieris Pharmaceuticals stock options (Q4 2017 – Q3 2022)
| Q4 2017 | 27,000 | 156,000 |
|---|---|---|
| Q1 2018 | 244,000 | 973,000 |
| Q2 2018 | 1,000 | 486,000 |
| Q3 2018 | 0 | 363,000 |
| Q4 2018 | 0 | 84,000 |
| Q1 2019 | 0 | 0 |
| Q2 2019 | 5,000 | 0 |
| Q3 2019 | 693,000 | 305,000 |
| Q4 2019 | 107,000 | 0 |
| Q1 2020 | 0 | 0 |
| Q2 2020 | 0 | 0 |
| Q3 2020 | 67,000 | 50,000 |
| Q4 2020 | 0 | 56,000 |
| Q1 2021 | 55,000 | 0 |
| Q2 2021 | 2,104,000 | 1,840,000 |
| Q3 2021 | 1,594,000 | 1,881,000 |
| Q4 2021 | 903,000 | 108,000 |
| Q1 2022 | 591,000 | 68,060 |
| Q2 2022 | 222,000 | 24,000 |
| Q3 2022 | 126,000 | 18,000 |